IS3871A - Hliðstæðar aðferðir til framleiðslu á Quinuclidine afleiðum - Google Patents

Hliðstæðar aðferðir til framleiðslu á Quinuclidine afleiðum

Info

Publication number
IS3871A
IS3871A IS3871A IS3871A IS3871A IS 3871 A IS3871 A IS 3871A IS 3871 A IS3871 A IS 3871A IS 3871 A IS3871 A IS 3871A IS 3871 A IS3871 A IS 3871A
Authority
IS
Iceland
Prior art keywords
production
similar methods
quinuclidine derivatives
quinuclidine
derivatives
Prior art date
Application number
IS3871A
Other languages
English (en)
Other versions
IS1611B (is
Inventor
Ito Fumitaka
Kondo Hiroshi
Shimada Kaoru
Nakane Masami
A. Lowe John Iii
J. Rosen Terry
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24845673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS3871(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS3871A publication Critical patent/IS3871A/is
Publication of IS1611B publication Critical patent/IS1611B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS3871A 1991-05-31 1992-05-29 Hliðstæðar aðferðir til framleiðslu á Quinuclidine afleiðum IS1611B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70840491A 1991-05-31 1991-05-31

Publications (2)

Publication Number Publication Date
IS3871A true IS3871A (is) 1992-12-02
IS1611B IS1611B (is) 1996-10-18

Family

ID=24845673

Family Applications (1)

Application Number Title Priority Date Filing Date
IS3871A IS1611B (is) 1991-05-31 1992-05-29 Hliðstæðar aðferðir til framleiðslu á Quinuclidine afleiðum

Country Status (41)

Country Link
US (3) US5807867A (is)
EP (1) EP0587723B1 (is)
JP (2) JPH0733386B2 (is)
KR (1) KR100214905B1 (is)
CN (1) CN1048492C (is)
AP (1) AP299A (is)
AT (1) ATE135006T1 (is)
AU (1) AU657552B2 (is)
BG (1) BG61694B1 (is)
BR (1) BR9206073A (is)
CA (1) CA2102179C (is)
CZ (1) CZ281403B6 (is)
DE (4) DE9290063U1 (is)
DK (1) DK0587723T3 (is)
EG (1) EG19944A (is)
ES (1) ES2084361T3 (is)
FI (1) FI114475B (is)
GR (1) GR3019687T3 (is)
GT (1) GT199200028A (is)
HU (1) HU217548B (is)
IE (1) IE72473B1 (is)
IL (1) IL102008A (is)
IS (1) IS1611B (is)
LU (1) LU91293I2 (is)
MA (1) MA22539A1 (is)
MX (1) MX9202554A (is)
NL (1) NL300250I2 (is)
NO (2) NO302701B1 (is)
NZ (2) NZ270673A (is)
OA (1) OA09867A (is)
PL (1) PL171379B1 (is)
PT (1) PT100546B (is)
RO (1) RO110499B1 (is)
RU (1) RU2103269C1 (is)
SK (1) SK390692A3 (is)
TW (1) TW204349B (is)
UA (1) UA27776C2 (is)
UY (1) UY23422A1 (is)
WO (1) WO1992021677A1 (is)
YU (1) YU48995B (is)
ZA (1) ZA923942B (is)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9290063U1 (de) * 1991-05-31 1994-02-24 Pfizer Inc., New York, N.Y. Chinuclidin-Derivate
BR9206161A (pt) * 1991-06-20 1995-10-31 Pfizer Derivados fluoroalcoxibenzilamino de heterociclos contendo nitrogénio
EP1114823A3 (en) * 1992-08-19 2001-07-18 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
US5886009A (en) * 1992-11-12 1999-03-23 Pfizer Inc. Quinuclidine derivative as a substance P antagonist
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists for the inhibition of angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
CN1291099A (zh) * 1998-03-19 2001-04-11 武田药品工业株式会社 杂环化合物,其生产和用途
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
KR100885986B1 (ko) 1999-11-03 2009-03-03 에이엠알 테크놀로지, 인크. 노르에피네프린, 도파민 및 세로토닌의 재흡수를 방지하기위한 아릴 및 헤테로아릴 치환된테트라하이드로이소퀴놀린 및 이들의 용도
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
CA2415532C (en) 2000-07-11 2010-05-11 Albany Molecular Research, Inc. Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
CZ200434A3 (cs) * 2001-07-20 2005-02-16 Pfizer Products Inc. Léčivo pro léčení abnormálního úzkosného chování u domácích zvířat a způsob screeningu zkoušené sloučeniny za účelem stanovení anxiolytické účinnosti u psů
US6686507B2 (en) 2002-03-06 2004-02-03 Pfizer Inc Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
ZA200505733B (en) * 2003-01-21 2006-10-25 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
WO2005045395A2 (en) * 2003-10-27 2005-05-19 Meyer Donald W Method of detecting bovine spongiform encephalopathy
EP1689721B1 (en) * 2003-11-26 2010-07-14 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
CA2554823A1 (en) * 2004-01-30 2005-09-09 Pfizer Products Inc. Nk-1 receptor antagonists to improve anesthesia recovery
LT1713504T (lt) * 2004-01-30 2017-09-11 Zoetis Services Llc Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms
BRPI0507334A (pt) 2004-02-02 2007-07-03 Pfizer Prod Inc processo para a preparação de -1(2s,3s)-2-benzidril-n-(5-terc-butil-2-metoxibenzila)q uinuclidin-3-amina
KR101389246B1 (ko) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
ZA200800440B (en) 2005-07-15 2009-12-30 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR20100126467A (ko) 2008-03-03 2010-12-01 타이거 파마테크 티로신 키나아제 억제제
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
DK2729147T3 (en) 2011-07-04 2017-12-18 Irbm - Science Park S P A NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
JP7158425B2 (ja) 2017-06-30 2022-10-21 チェイス セラピューティクス コーポレイション Ｎｋ－１アンタゴニスト組成物およびうつ病の処置における使用法
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
US20210015834A1 (en) 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
KR102102109B1 (ko) * 2018-07-10 2020-04-20 성균관대학교산학협력단 N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP4117673A1 (en) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Treatment of stem cell deficiency
AT527172A1 (de) 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
EP0532527B1 (en) * 1990-06-01 1994-11-09 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
DE4026743A1 (de) * 1990-08-24 1992-02-27 Teves Gmbh Alfred Blockiergeschuetzte bremsanlage fuer kraftfahrzeuge
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
DE9290063U1 (de) * 1991-05-31 1994-02-24 Pfizer Inc., New York, N.Y. Chinuclidin-Derivate
ATE195867T1 (de) * 1991-09-20 2000-09-15 Glaxo Group Ltd Neue medizinische indikation für tachykinin- antagonisten
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
ATE194342T1 (de) * 1996-01-19 2000-07-15 Lonza Ag Verfahren zur herstellung von optisch aktivem 3- chinuclidinol
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
TW204349B (is) 1993-04-21
ATE135006T1 (de) 1996-03-15
HU217548B (hu) 2000-02-28
JPH06504292A (ja) 1994-05-19
NL300250I2 (nl) 2007-03-01
JP2645225B2 (ja) 1997-08-25
DE122006000066I1 (de) 2007-03-22
CZ281403B6 (cs) 1996-09-11
PT100546B (pt) 1999-12-31
US6222038B1 (en) 2001-04-24
NO302701B1 (no) 1998-04-14
FI935297A0 (fi) 1993-11-29
IE921729A1 (en) 1992-12-02
IE72473B1 (en) 1997-04-23
DK0587723T3 (da) 1996-04-01
YU56492A (sh) 1995-03-27
AP9200384A0 (en) 1992-07-31
US5939433A (en) 1999-08-17
NO2007003I2 (no) 2011-04-18
PT100546A (pt) 1993-08-31
RO110499B1 (ro) 1996-01-30
UA27776C2 (uk) 2000-10-16
BG98248A (bg) 1994-07-29
NZ270673A (en) 1997-07-27
EG19944A (en) 1997-02-27
RU2103269C1 (ru) 1998-01-27
EP0587723A1 (en) 1994-03-23
HUT70151A (en) 1995-09-28
KR100214905B1 (ko) 1999-08-02
JPH07285965A (ja) 1995-10-31
NO934312D0 (no) 1993-11-29
YU48995B (sh) 2003-04-30
NZ242956A (en) 1995-06-27
SK278788B6 (sk) 1998-02-04
IL102008A0 (en) 1992-12-30
DE9290063U1 (de) 1994-02-24
GT199200028A (es) 1993-11-20
CN1048492C (zh) 2000-01-19
JPH0733386B2 (ja) 1995-04-12
NO934312L (no) 1993-11-29
CA2102179A1 (en) 1992-12-01
CZ390692A3 (en) 1994-02-16
FI114475B (fi) 2004-10-29
AP299A (en) 1994-01-14
MA22539A1 (fr) 1992-12-31
GR3019687T3 (en) 1996-07-31
IL102008A (en) 1995-12-08
EP0587723B1 (en) 1996-03-06
ZA923942B (en) 1993-11-29
AU657552B2 (en) 1995-03-16
CA2102179C (en) 1998-10-27
AU1990192A (en) 1993-01-08
ES2084361T3 (es) 1996-05-01
DE69208877D1 (de) 1996-04-11
HU9303393D0 (en) 1994-03-28
NL300250I1 (nl) 2007-02-01
WO1992021677A1 (en) 1992-12-10
MX9202554A (es) 1992-11-01
PL171379B1 (en) 1997-04-30
SK390692A3 (en) 1998-02-04
BR9206073A (pt) 1994-12-06
US5807867A (en) 1998-09-15
FI935297L (fi) 1993-11-29
NO2007003I1 (no) 2007-03-26
DE122006000066I2 (de) 2007-12-06
BG61694B1 (bg) 1998-03-31
DE69208877T2 (de) 1996-07-25
CN1067428A (zh) 1992-12-30
IS1611B (is) 1996-10-18
LU91293I2 (fr) 2007-02-06
OA09867A (en) 1994-08-15
UY23422A1 (es) 1992-11-12

Similar Documents

Publication Publication Date Title
IS1611B (is) Hliðstæðar aðferðir til framleiðslu á Quinuclidine afleiðum
IS1867B (is) Hliðstæð aðferð til framleiðslu á kristölluðum oxaþíólan afleiðum
IS3915A (is) Aðferð til framleiðslu á benzanilíð afleiðum
IS3914A (is) Aðferð til framleiðslu á benzanilíð afleiðum
IS4201A (is) Aðferð til framleiðslu á Benzofuran afleiðum
IS3936A (is) Hliðstæð aðferð til framleiðslu á vatnsuppleysanlegum kamptóþesín afleiðum
IS3994A (is) Hliðstæð aðferð til framleiðslu á indole afleiðum
IS3945A (is) Aðferð til framleiðslu á ediksýruafleiðum
IS3954A (is) Hliðstæð aðferð við framleiðslu nýrra peptíðafleiða
FI20031381A7 (fi) Menetelmä antihistamiinisten 4-difenyylimetyylipiperidiinijohdannaisten valmistamiseksi
NO892926L (no) Fremgangsmaate for syntese av sukrosederivater.
NO912051D0 (no) Fremgangsmaate for fremstilling av azolderivater.
NO892936L (no) Fremgangsmaate for fremstilling av furanderivater.
IS3827A (is) Hliðstæð aðferð við framleiðslu á pýrról[2,3 b]pýridínum
NO880910D0 (no) Fremgangsmaate for fremstilling av chromonderivater.
FI882165A7 (fi) Menetelmä 4-amino-androsteenidioni-johdannaisten valmistamiseksi.
NO891588D0 (no) Fremgangsmaate for fremstilling av fosfonoalkylpurinderivater.
IS4079A (is) Milliefni til framleiðslu á súbstitúeruðum bensimidasólum
NO883145L (no) Fremgangsmaate til fremstilling av tienoimidazol-derivater.
MX9204847A (es) Procedimiento para la produccion de acetato de metilo.
FI915785L (fi) Menetelmä 3-asemassa substituoitujen tiofeenien valmistamiseksi
DK56694A (da) Fremgangsmåde til fremstilling af cephemderivater
DK382886D0 (da) Fremgangsmaade til fremstilling af hormonfaktorderivater
NO900381D0 (no) Fremgangsmaate for fremstilling av nafthalenderivater.
NO178577C (no) Fremgangsmåte til fremstilling av cefalosporin